Hematology | Clinical

FDA Grants Fast Track Designation to Rilzabrutinib for Treatment of Immune Thrombocytopenia

November 18, 2020

The FDA has granted a Fast Track designation to rilzabrutinib, an oral investigational Bruton’s tyrosine kinase inhibitor, for the treatment of immune thrombocytopenia. The drug was previously granted Orphan Drug designation for this indication.

Sequencing TP53 Mutations in Myeloid Neoplasms

November 17, 2020

Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.

Azacitidine/Venetoclax Represents New Gold Standard for Older Patients with Treatment-Naïve AML

November 13, 2020

In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.

Outcomes in Lower-Risk MDS Advance As Novel Strategies Emerge

November 04, 2020

Outcomes for patients with myelodysplastic syndrome range from a median of 5.3 years in the lower-risk population to 8.4 months among patient with very high-risk disease. These outcomes are changing as novel therapies for the lower-risk population enter the treatment landscape.